You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百濟神州(06160.HK)擬1.95億元收購凱得所持百濟神州生物藥業5%股權實現全控
格隆匯 10-05 07:53

格隆匯 10 月 5日丨百濟神州(06160.HK)發佈公告,2017年3月,公司的全資子公司BeiGene (Hong Kong) Co., Limited.(“百濟神州(香港)”)與廣州開發區的聯屬公司廣州高新區科技控股集團有限公司(前稱廣州凱得科技發展有限公司)(“凱得”)成立合營企業,在廣州建立商業規模的生物製劑生產工廠。根據合資協議的條款,百濟神州(香港)持有合營企業百濟神州生物藥業有限公司的95%股權,而凱得持有其5% 股權。此外,凱得向百濟神州生物藥業提供人民幣9億元的貸款,每年固定利率為8%,於2023年4月到期,以支持生產工廠的建設。

2020年9月28日,百濟神州(香港)與凱得訂立購股協議,以(i)按約人民幣1.95億元總購買價收購凱得所持有百濟神州生物藥業的5%股權,及(ii)使百濟神州生物藥業悉數償還股東貸款及利息,總額約為人民幣11.5億元。此項交易完成後,(i)公司將通過其全資子公司百濟神州(香港)持有百濟神州生物藥業的100%股權,惟須經當地市場監督管理局批准(預期於2020年第四季度取得),(ii)股東貸款已悉數償還並已終止,及(iii)百濟神州(香港)與凱得訂立日期為2017年4月11日的經修訂百濟神州生物藥業股權合資合約將於監管批准日期終止。

為撥付購買5%股權及償還股東貸款,公司與民生銀行上海自貿試驗區分行訂立一年期定期貸款(可續期最長三年),借款金額約為1.18億美元併購貸款,以及額外的8000萬美元營運資金貸款。此外,作為民生銀行貸款的信用增級措施,百濟神州生物藥業與公司主要股東Hillhouse Capital Advisors, Ltd.的聯屬公司訂立為期最長37個月的定期貸款,以(i)通過一般公司貸款借入最多人民幣1億元,及(ii)通過信用增級貸款借入最多人民幣4億元,該等貸款僅可於需要時用於償還民生銀行貸款。公司董事易清清與Hillhouse有關聯。民生銀行貸款及Hillhouse貸款的應付總利息和費用為每年5.75%。

公司計劃於2020年第四季度提取民生銀行貸款下所有可用的約1.98億美元,而百濟神州生物藥業已根據民生銀行貸款合同的要求提取Hillhouse貸款下人民幣1億元一般公司貸款。Hillhouse貸款下剩餘的人民幣4億元信用增級貸款將不會被提取,除非公司及百濟神州生物藥業決定將來使用該貸款償還部分民生銀行貸款。Hillhouse貸款為公司向關連人士獲得的財務資助,但是按一般商業條款或更佳條件進行,且不以公司任何資產作抵押,因此獲豁免遵守香港上市規則的關連交易規定。 

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account